Pappas Capital Announces the Passing of…

NOVATO, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Clay B. Siegall, Ph.D. and Matthew Fust to the company's Board of Directors effective January 30, 2014. Dr. Siegall, currently President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., and Mr. Fust, formerly Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. will serve as independent directors for Ultragenyx. With these additions, Ultragenyx extends gratitude and appreciation for the counsel provided by Mr. Ben Auspitz, who has resigned from his position on the Board effective January 30, 2014.